Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,575
  • Shares Outstanding, K 2,513
  • Annual Sales, $ 710 K
  • Annual Income, $ -21,410 K
  • 60-Month Beta 0.21
  • Price/Sales 6.63
  • Price/Cash Flow N/A
  • Price/Book 0.72
Trade LGVN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.15
  • Number of Estimates 2
  • High Estimate -1.60
  • Low Estimate -2.70
  • Prior Year -2.20
  • Growth Rate Est. (year over year) +2.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6200 +6.17%
on 04/12/24
5.4700 -68.56%
on 04/08/24
-2.1000 (-54.97%)
since 03/22/24
3-Month
1.6200 +6.17%
on 04/12/24
8.7360 -80.31%
on 01/25/24
-6.4800 (-79.02%)
since 01/24/24
52-Week
1.6200 +6.17%
on 04/12/24
44.0000 -96.09%
on 05/09/23
-26.9800 (-94.01%)
since 04/24/23

Most Recent Stories

More News
Longeveron (NASDAQ: LGVN) Closes on Warrant Exercise Offering, Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7200 (-5.49%)
Longeveron (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M

Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7200 (-5.49%)
Longeveron (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7200 (-5.49%)
Longeveron (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7200 (-5.49%)
Longeveron (NASDAQ: LGVN) Discusses 2023 Progress, 2024 Plans in Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for...

LGVN : 1.7200 (-5.49%)
Longeveron (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock....

LGVN : 1.7200 (-5.49%)
Longeveron (NASDAQ: LGVN) Reports on Year-End 2023 Financial Results

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report...

LGVN : 1.7200 (-5.49%)
Longeveron (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The...

LGVN : 1.7200 (-5.49%)
Longeveron (NASDAQ: LGVN) Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS

Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS...

LGVN : 1.7200 (-5.49%)
Longeveron’s (NASDAQ: LGVN) Long-Term Follow-Up Data from ELPIS I Trial Presented at 2023 Annual Scientific Sessions

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions including hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7200 (-5.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 1.9567
2nd Resistance Point 1.8933
1st Resistance Point 1.8067
Last Price 1.7200
1st Support Level 1.6567
2nd Support Level 1.5933
3rd Support Level 1.5067

See More

52-Week High 44.0000
Fibonacci 61.8% 27.8108
Fibonacci 50% 22.8100
Fibonacci 38.2% 17.8092
Last Price 1.7200
52-Week Low 1.6200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar